[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_1185 

# __Tailored protection for symptomatic and asymptomatic patients__

## Articles mentionning this Benefit

* [Contributions to the mitigation of the COVID-19 pandemic](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_245.md)

## Category to which it belongs

* [Minimized transmission and spread risk while ensuring effective infection control, prevention, and containment measures against diseases like coronavirus.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_17.md)

## Description of actual returns pertaining to this benefit

* [Private investors can invest in research to develop targeted protection measures, potentially leading to the development of new therapeutics or improved vaccine strategies.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_1325.md)

## Name of the Benefit

Evaluating differences in efficacy based on symptoms allows for tailored protection strategies, ensuring appropriate measures are taken for each group

## Risks which can benefit from this action

* [Evaluate efficacy differences based on symptoms](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_1186.md)

## Stakeholders benefitting from this Benefit

* [Reinfected patients with and without symptoms](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_464.md)

